Location History:
- West Sussex, GB (2016 - 2017)
- Horsham, GB (2018 - 2024)
Company Filing History:
3 out of 117 
3 out of 4 
2 out of 39 Years Active: 2016-2025
Title: The Innovations of Andrew Douglas Baxter
Introduction
Andrew Douglas Baxter is a notable inventor based in Horsham, GB. He has made significant contributions to the field of anti-angiogenic treatments, with a focus on various medical conditions. Baxter holds a total of 6 patents, showcasing his innovative approach to addressing complex health issues.
Latest Patents
Baxter's latest patents include advancements in SRPK1 inhibitors, which are designed for anti-angiogenic treatments. These treatments target conditions such as ocular neovascularization and cancer, as well as hyperpermeability disorders, neuropathic and neurodegenerative disorders, and pain management. Additionally, he has developed methods for treating or preventing fibrosis and compounds for use in these methods. Another significant patent involves 1-methyl-1H-pyrazol-3-yl derivatives, which are aimed at treating neovascular diseases. This patent focuses on anti-angiogenic treatments and compounds that address conditions associated with abnormal angiogenesis or the over-production of pro-angiogenic VEGFxxx isoforms in the eye.
Career Highlights
Throughout his career, Baxter has worked with esteemed institutions such as University College Dublin and Exonate Limited. His work has been instrumental in advancing medical treatments that improve patient outcomes.
Collaborations
Baxter has collaborated with notable colleagues, including Breandan Kennedy and Alison Reynolds. Their combined expertise has contributed to the success of various projects and innovations.
Conclusion
Andrew Douglas Baxter's contributions to the field of anti-angiogenic treatments highlight his dedication to innovation in medicine. His patents reflect a commitment to addressing critical health challenges through scientific advancements.